The SGLT2 Inhibitor Canagliflozin Suppresses Growth and Enhances Prostate Cancer Response to Radiotherapy

Scientists showed that well-tolerated doses of canagliflozin suppressed proliferation and survival of androgen-sensitive and insensitive human prostate cancer cells and tumors and sensitize them to radiotherapy.